US53220K5048
US53220K5048
Ligand Pharmaceuticals Incorpor
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 268.087.000 | 167.133.000 | 60.4% |
| Cost of Revenue | 14.549.000 | 11.074.000 | 31.4% |
| Gross Profit | 253.538.000 | 156.059.000 | 62.5% |
| 206.339.000 | 133.038.000 | 55.1% | |
| Operating Income | 47.199.000 | 23.021.000 | 105.0% |
| Pretax Income | 158.960.000 | 2.518.000 | 6212.9% |
| Net Income Common Stockholders | 124.453.000 | -4.032.000 | 3186.6% |
| -- | -- | -- | |
| -- | -- | -- |